Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
305.8 USD | +1.59% | -0.01% | +6.17% |
May. 28 | US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment | RE |
May. 28 | Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.17% | 161B | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
-0.45% | 160B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Redburn Adjusts Price Target on Amgen to $170 From $180, Keeps Sell Rating